TICKERNERD
Menu
BYSIBYSIHealthcare · Biotechnology

BYSI Stock Forecast: BeyondSpring, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$0.72
−0.01% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 21 of 100 as at 22 Aug 2026 — in the weakest quartile.

Market cap
$29.6M
Ticker Nerd rank
21 / 100
Median analyst target
—
Analysts covering
2
Total return, dividends reinvested
1W
−14.2%
1M
−42.4%
YTD
−55.8%
1Y
−59.1%
From 52W high
−69.4%
From 52W low
+1.1%
$0.71
$2.35
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BYSI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores BeyondSpring, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
21 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
86
Volatility
64
Issuance
55
Accruals
54
Momentum
43
Revisions
25
Value
21
Quality
9
Growth
8

Size (86): Smaller than most of the companies we track.

Growth (8): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BYSI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BYSI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$1.50$2.00Oct 25Jan 26Apr 26Jul 26BYSI

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 May 2023BairdMaintainsOutperform$4.00 → $1.25
2 Dec 2021B of A SecuritiesDowngradeUnderperform—
2 Dec 2021JefferiesDowngradeHold—
1 Dec 2021HC Wainwright & Co.DowngradeNeutral—
20 Sept 2021HC Wainwright & Co.MaintainsBuy—
9 Sept 2021BairdInitiatesOutperform—
4 Aug 2021HC Wainwright & Co.UpgradeBuy—
5 Apr 2021HC Wainwright & Co.DowngradeNeutral—
11 Jan 2021B of A SecuritiesInitiatesBuy—
29 Dec 2020Evercore ISI GroupInitiatesOutperform—
15 June 2020HC Wainwright & Co.MaintainsBuy—
30 Mar 2020HC Wainwright & Co.MaintainsBuy—
7 Feb 2020JefferiesInitiatesBuy—
10 Jan 2020NomuraInitiatesBuy—
10 Jan 2020Nomura InstinetInitiatesBuy—
3 Dec 2019William BlairInitiatesOutperform—
22 June 2018Maxim GroupMaintainsBuy—
4 Apr 2017Rodman & RenshawInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BYSI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

BYSI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

BeyondSpring, Inc. (BYSI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−36.0×

Cheaper than 97% of US stocks

Price / sales
—
Price / book
−1.0×

Cheaper than 95% of US stocks

EV / EBITDA
−2.7×

Cheaper than 73% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
4.2%

Higher than 52% of US stocks

Return on assets
−22.9%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

BYSI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BYSIBeyondSpring, Inc.$29.6M
21
LTRNLantern Pharma, Inc.$29.9M
56
ACTUActuate Therapeutics, Inc.$29.1M
27
KYNBKyntra Bio, Inc.$30.4M
44
NXTCNextCure, Inc.$28.8M
76
ESLAEstrella Immunopharma, Inc.$30.9M
26
DYAIDyadic International, Inc.$27.6M
19

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own BeyondSpring, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BYSI news & analysis

BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewsWire · 14 Aug 2026positive

BeyondSpring reported its second-quarter 2026 financial results and provided a corporate update. The update highlights ASCO 2026 data demonstrating a long-term survival benefit of Plinabulin/Docetaxel and Pembrolizumab in metastatic non-small cell lung cancer following progression on first-line immune checkpoint inhibitor therapy.

Why it matters — BYSI watchers would care because the ASCO 2026 data provides encouraging evidence of a long-term survival benefit for Plinabulin-based combinations in a difficult-to-treat NSCLC patient population.

FAQ

Frequently asked questions about BYSI stock

Is BYSI stock a buy right now?

Of the 2 analysts covering BeyondSpring, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BeyondSpring, Inc. 21 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BYSI?

As at 22 Aug 2026, BeyondSpring, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (86 of 100).

What is the BYSI stock forecast for 2030?

No analyst covering BeyondSpring, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BYSI are extrapolating price history, which says nothing about the business.

How has BYSI stock performed over the past year?

BeyondSpring, Inc. returned -59.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does BeyondSpring, Inc. do?

BeyondSpring Inc. is a clinical-stage biopharmaceutical company engaged in the development of innovative cancer therapies.

What is the latest news on BYSI?

The most recent item we track (GlobeNewsWire, 14 Aug 2026): "BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update". BeyondSpring reported its second-quarter 2026 financial results and provided a corporate update. The update highlights ASCO 2026 data demonstrating a long-term survival benefit of Plinabulin/Docetaxel and Pembrolizumab in metastatic non-small cell lung cancer following progression on first-line immune checkpoint inhibitor therapy.

Company

About BeyondSpring, Inc.

BeyondSpring Inc. is a clinical-stage biopharmaceutical company engaged in the development of innovative cancer therapies. The primary function of BeyondSpring is to advance novel therapeutics that address unmet needs in oncology, with a focus on improving patient outcomes through scientific innovation. The company is particularly noted for its development pipelines targeting a range of cancer types, utilizing mechanisms that enhance the efficacy of existing treatments or target cancer pathways more precisely. BeyondSpring's flagship product, Plinabulin, is under investigation for its potential to reduce chemotherapy-induced neutropenia and for its anti-cancer properties. This dual functionality exemplifies the company’s strategic focus on mechanisms that can provide both ameliorative and therapeutic effects, making it a unique player in the oncology sector. In the financial market, BeyondSpring Inc. holds significance as part of the biopharmaceutical industry’s ongoing efforts to revolutionize cancer treatment paradigms. Investors and stakeholders keep a close watch on the advancements from BeyondSpring due to the company's potential to contribute significantly to clinical developments in cancer therapy.

CEO Dr. Lan Huang Ph.D. · 44 employees · United States · https://beyondspringpharma.com